ERBB2 and breast carcinoma: For patients with Her‐2 positive advanced breast cancer, a PHOEBE study showed median progression‐free survival was significantly longer with pyrotinib‐combined regiments (12.5 months [95% CI 9.7‐not reached]) than with lapatinib plus capecitabine (6.8 months [95% CI 5.4‐8.1]).5